Meloxicam (Meloxicam) Patent Expiration, LOE Window & CMS Spending

Meloxicam (Meloxicam) by Avondale: Off-Patent Genericized (AB Competition), 14 AB generics, $80.8M 2024 CMS Part D & Medicaid spend, and $900 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAvondale
FDA Application & PathwayN021530 (NDA)
Exclusivity / Cliff HorizonOff-Patent Genericized (AB Competition)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors14
2024 CMS Total Public Spend$80.8M
2024 Medicare Part D Spend$51.5M
2024 Medicaid Spend$29.3M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($900 intro WAC)